ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens
23 Agosto 2024 - 12:39PM
Business Wire
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering
biotech/agtech R&D company dedicated to developing therapeutic,
medicinal and nutritional product candidates derived from
proprietary algal cultures, reports favorable results from its
latest 42-day study with its product targeting coccidiosis in
broiler chickens.
The study, which was conducted in collaboration with a major
global animal health company and replicated real-world poultry
production environments, further validates the efficacy of ZIVO’s
non-antibiotic, immune-modulating product designed for the
treatment of coccidiosis. Funded by the major animal health
company, the study focused on the overall health and productivity
of birds challenged with the coccidiosis-causing parasite, Eimeria,
while comparing administration of ZIVO’s product alone or in
combination with either an ionophore-based treatment or a
coccidiosis vaccine versus birds treated with the ionophore or
vaccination alone. Uninfected/untreated healthy birds and
infected/untreated birds served as negative and positive disease
controls, respectively.
In this study, broiler chickens infected with coccidiosis and
treated with ZIVO’s product in combination with an anticoccidial
ionophore or vaccination exhibited statistically significant
improvements in both growth performance (as measured by feed
conversion ratio, FCR) and clinical signs of disease (as measured
by intestinal lesion scores), compared with chickens that received
only the ionophore or vaccine. With respect to FCR over the 42-day
grow-out period, groups treated with ZIVO’s product in combination
with either the ionophore or vaccination performed on par with the
healthy, uninfected control group.
“We are delighted to report favorable findings from this new
study that confirm the effectiveness of our product to support
poultry health and productivity in the presence of coccidiosis.
These results further demonstrate the versatility of our product
candidate not only because of its ability to enhance currently
available treatment options, but also because of its standalone
treatment potential as validated in numerous prior studies.
Maintaining feed conversion ratios comparable to uninfected birds
is a notable finding that underscores the value our product offers
the poultry industry,” said John Payne, Chairman and CEO of ZIVO
Bioscience.
“Coccidiosis is one of the most challenging and costly diseases
in poultry production, and the ability to improve outcomes using
our product in combination with existing interventions represents a
potential breakthrough in disease management. We look forward to
advancing our discussions global animal health companies in
preparation for commercial markets,” he added.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight
loss, decreased performance and increased mortality in poultry.
This disease represents a significant economic challenge for the
global poultry industry, and as indicated by a 2020 study, the
estimated annual costs are approximately $14 billioni. Products for
treating coccidiosis are mostly antibiotic- or ionophore-based, and
no significant new commercial technology has been introduced in the
past 60 years. The global poultry industry spends more than $1.5
billion annually on coccidiosis control, primarily using
decades-old compounds that industry and consumers alike want to
replace due to the risks of developing drug resistance. Coccidiosis
is a common disease for chickens, especially among young chicks,
and can be fatal or result in compromised digestion.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, including with respect
to the Company’s product candidate’s potential to generate revenues
and the expected time frame for results of future studies. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. Although
ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that we will be unable to increase production sufficient to meet
our expected demand; risks that our products may not be ready for
commercialization in a timely manner or at all; risks that our
products will not perform as expected based on results of our
pre-clinical and clinical trials; our ability to raise additional
funds; uncertainties inherent in the development process of our
products; changes in regulatory requirements or decisions of
regulatory authorities; the size and growth potential of the
markets for our products; the results of clinical trials, our
ability to protect our intellectual property rights and other
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
_________________________ i Blake, D.P., Knox, J., Dehaeck, B.
et al. Re-calculating the cost of coccidiosis in chickens. Vet Res
51, 115 (2020). https://doi.org/10.1186/s13567-020-00837-2
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240823637788/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com
LHA Investor Relations Tirth T. Patel (212) 201-6614
tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Zivo Bioscience (NASDAQ:ZIVO)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024